Prevnar13 (Pfizer) and Synflorix (GSK) both are Pneumococcal Conjugate Vaccines indicated for active immunization of infants and children from 6 weeks up to 5 years of age against invasive Pneumococcal diseases. Prevnar protects against 13 common types whereas Synflorix protects against 10 common types of Streptococcus pneumoniae.
Both Prevnar 13 and Synflorix are better than the older Prevnar which provides protection against only 7 serotypes. Prevnar 13 has already replaced Prevnar since its arrival in 2011. There is no clinical data available till now to prove which of the two, Synflorix vs Prevnar13 is better in terms of efficacy. Both the vaccines can be interchanged for the 4 dose series.
Prevnar 13 costs double the amount of Synforix for its added protection against 3 extra serotypes and its brand value Pfizer USA which had monopoly for Pneumococcal conjugate vaccines till Synflorix was launched.